- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00258193
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Pharmacodynamic Effects of Orally Administered 100ug and 1000ug QD MD-1100 Acetate on Gastrointestinal Transit in Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)
- The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
The secondary objectives of this trial are:
- To compare the dose ranging pharmacodynamic effects of placebo, and 100 and 1000 ug MD-1100 Acetate once daily on time to first bowel movement after first drug intake.
- To describe and summarize the effects of placebo, and 100 and 1000 ug MD-1100 Acetate once daily on stool frequency, stool consistency, ease of passage and sensation of incomplete evacuation during the Treatment Period relative to Baseline.
Study Overview
Detailed Description
Using a double-blind, randomized, placebo-controlled, parallel group study design, the effects of placebo and two different doses of orally administered MD-1100 Acetate on gastric emptying, small bowel transit and total colonic transit will be compared and evaluated in patients with C-IBS.
After eligibility is confirmed, the patient will return for baseline measurement of colonic transit to ensure that the transit profile is not greater than the mean transit profile of healthy controls in order to avoid a ceiling effect. A patient must have a geometric center of ≤2.65 at 24 hours, or ≤3.0 at 24 hours and ≤3.9 at 48 hours in order to be randomized to a 5-day Treatment Period of study medication. Eligible patients will receive oral study medication for 5 days during which colonic transit will be measured.
Approximately 36 (n=36) patients will be randomized to one of three different treatment groups: placebo (n=12), 100 ug MD-1100 (n=12), or 1000 ug MD-1100 (n=12). All dosing of study medication will be supervised at the Mayo Clinic.
Patients will complete a daily Stool Diary to record bowel habits for 5 consecutive days during the Pretreatment Period and then for the 5 consecutive days of the Treatment PeriodPhysical examinations, vital signs, electrocardiograms, and clinical laboratory tests will be performed throughout the study and adverse events will be recorded for safety evaluation.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States
- Mayo Clinic Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient agrees to use a medically accepted, double-barrier form of contraception (e.g., IUD and condom) during participation;
- No evidence of pelvic floor dysfunction and the completion of a negative digital rectal exam prior to the first dose of study medication;
- Absence of an evacuation disorder as defined per protocol;
- Patients must meet ROME II Criteria for C-IBS;
- The patient's Baseline Colonic Transit Test must show a geometric center (GC) ≤ 2.65 at 24 hours, or ≤ 3.0 at 24 hours and ≤ 3.9 at 48 hours.
Exclusion Criteria:
- History of clinically-significant manifestations of any major system organ class;
- History of inflammatory bowel disease or gastric ulcers;
- Significant GI surgery within 6 months;
- Clinically-significant prolonged diarrhea within 60 days;
- Special dietary habit and/or an intense physical workout program within 4 weeks;
- Certain drug hypersensitivities
- History of alcoholism or drug addiction within 12 months;
- Receipt of an investigational drug during the study or within 30 days;
- Use of any prescription medication or OTC, non-prescription medications disallowed by the protocol within 7 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
(Safety) AEs to be collected beginning with patient's first administration of study medication through final study visit
|
Clinical chemistry, hematology, and urinalyses to be performed before and after the Treatment Period
|
Cardiac safety will be monitored by ECG recordings
|
(Efficacy) Primary endpoints for analysis of efficacy are the colonic geometric center (GC) at 24 hours and ascending colon t1/2 values.
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary transit endpoints will be gastric emptying t1/2, colonic filling at 6 hours, colonic GC at additional time points including 48 hours, and time to first bowel movement after the first dose of medication.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Camilleri, MD, Mayo Clinic Foundation
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Disease
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Colonic Diseases, Functional
- Colonic Diseases
- Intestinal Diseases
- Syndrome
- Irritable Bowel Syndrome
- Constipation
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Guanylyl Cyclase C Agonists
- Enzyme Activators
- Linaclotide
Other Study ID Numbers
- Protocol MCP-103-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on MD-1100 Acetate
-
Ironwood Pharmaceuticals, Inc.Completed
-
Mayo ClinicNational Cancer Institute (NCI)CompletedColorectal Cancer | Healthy, no Evidence of DiseaseUnited States
-
Jan Medical, Inc.TerminatedMild Traumatic Brain InjuryCanada
-
PharmaxisWithdrawnChronic Obstructive Pulmonary Disease
-
Jan Medical, Inc.CompletedBrain Concussion | Mild Traumatic Brain InjuryUnited States
-
Azura OphthalmicsSyneos Health; Cliantha ResearchCompletedDry Eye | Meibomian Gland DysfunctionCanada, Australia, New Zealand
-
Ethicon Endo-SurgeryRecruitingPediatric Procedures | Adult Hepato-pancreato-biliary (HPB) Procedures | Adult Lower Gastrointestinal Procedures | Adult Gastric Procedures | Adult Gynecological Procedures | Adult Urological Procedures | Adult Thoracic ProceduresUnited States, Canada, United Kingdom
-
Forest LaboratoriesCompletedEosinophilic EsophagitisUnited States
-
Forest LaboratoriesCompletedEosinophilic EsophagitisUnited States
-
Erasme University HospitalFonds de la Recherche Scientifique (fnrs)Not yet recruiting